Preliminary Experience and Morbidity Analysis of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy ( XXXX /HIPEC) from a Tertiary @entity5 Center in India.

@entity1 @entity43 @entity295 @entity5 @entity6177 @entity86 @entity91 @entity1744 @entity298
BACKGROUND: @entity298 ( @entity298 ) can arise directly from peritoneum (primary) or from regional spread of gastrointestinal and gynecological @entity5 . It is often considered a terminal event. @entity91 /HIPEC procedure provides encouraging outcomes in select sub-set of @entity1 with @entity298 . In this study we present our initial experience of this combined procedure from a tertiary @entity5 care center in India. MATERIALS AND METHODS: Between January 2014 to January 2015, 13 @entity1 underwent @entity91 + HIPEC procedure at our center. Preoperative assessment for cytoreduction was done using contrast CT-scan of the abdomen and staging laparoscopy. All procedures were performed by the same surgical team. After cytoreduction, HIPEC was performed by closed method. RESULTS: Median @entity1 age was 52 and median PCI was 13.5 (5-21). @entity43 were commonest origin of @entity298 in our series. All @entity1 had a complete cytoreduction with a median operative time of 8.3 hours. @entity86 was the commonest adverse event. In the immediate postoperative period, major complications were observed in 23% (3/13) of our @entity1 (1. @entity6177 . @entity295 and liver function derangement 3. @entity1744 which required a re-operation. Median hospital stay was 12 days (range 9-45 days) and there was no perioperative mortality. CONCLUSION: Our initial results indicate that @entity91 + HIPEC procedure can be performed with acceptable morbidity and no mortality. Appropriate case selection by a multi-disciplinary team is vital to achieve complete cytoreduction and optimize outcomes.
